Safety and Efficacy of Intracoronary Hypoxia-Preconditioned Bone Marrow Mononuclear Cell Administration for Acute Myocardial Infarction Patients: the China-Ami Randomized Controlled Trial

Xinyang Hu,Xin Huang,Qian Yang,Lihua Wang,Jianzhong Sun,Hongwei Zhan,Jianjing Lin,Zhaoxia Pu,Jun Jiang,Yong Sun,Meixiang Xiang,Xianbao Liu,Xiaojie Xie,Xia Yu,Zexin Chen,Hung-Fat Tse,Jianyi Zhang,Jian'an Wang

DOI: https://doi.org/10.1016/j.ijcard.2015.02.084

IF: 4.039

2015-01-01

International Journal of Cardiology

Abstract:BACKGROUND:Pre-clinical studies have shown that hypoxia preconditioning can enhance stem cell therapeutic potential for myocardial repair. We sought to investigate the safety and feasibility of intracoronary administration of hypoxia-preconditioned bone marrow mononuclear cells (HP-BMCs) for acute ST segment elevation myocardial infarction (STEMI).METHODS:We randomized 22 patients with acute STEMI to receive intracoronary administration of normoxia bone marrow mononuclear cells (N-BMCs) (n=11) or HP-BMCs (n=11) following successful reperfusion. Another 14 patients receiving standard therapy were recruited as control (n=14).RESULTS:There were no differences in the occurrence of major adverse cardiovascular events at 30 days and 1 year among three groups. There were significant improvement in the change of left ventricular end-diastolic volume (LVEDV) and end-systolic volume (LVESV) in HP-BMC group both at 6 and 12 months compared with N-BMCs or control group (P<0.05). No differences were observed in the change of left ventricular ejection fraction (LVEF), or wall motion score index (WMSI) among three groups. Nevertheless, WMSI was improved in HP-BMCs and N-BMC group (P<0.05, within group), but not in control. The ratio of myocardial perfusion defect determined by SPECT was significantly decreased in HP-BMCs and N-BMC groups at 6months compared with baseline (P<0.05, within group), but no significant differences were observed among three groups.CONCLUSIONS:Our results provide the first-in-man evidence that intracoronary administration of HP-BMCs following acute MI appears to be safe and feasible. These results provide the basis for future prospective randomized clinical trials in a larger patient cohort.CLINICAL TRIAL REGISTRATION INFORMATION:NCT01234181 (http://clinicaltrials.gov/ct2/show/NCT01234181?term=NCT01234181&rank=1).